It’s All About Choice

Real choices in healthcare are fundamental. They empower individuals, advance equity across healthcare systems and transcend healthcare altogether, fostering community resilience. But choice depends on commitment, requires investment and needs champions.

At AVAC, we are thinking intensely about how to be a champion for choice. Wherever our work takes us. Here’s what’s top of mind today.

Our newly launched initiative, The Choice Agenda (TCA), led by veteran advocate Jim Pickett, is hosting its next webinar in its series on HIV prevention, The Research Says Yes, YES, YES – Just Like That, Wednesday, July 13 at 9:00am ET / 1:00pm GMT / 15:00 SAST. Register now.

This webinar explores insights from HIV prevention and sexual health research that point to the many positive outcomes when we center and prioritize pleasure and sexual satisfaction in our interventions and prevention programming.

We’ll be featuring a discussion with experts:

• Christine M. Curley, University of Connecticut

• Dr. Joao Alves Neto, University of Minho (Portugal) and FACEFI (Brazil)

• Anne Philpott, The Pleasure Project

Get access to our previous webinars, register for what’s upcoming on The Choice Agenda webpage, and sign up with jimberlypickett@gmail.com to join the TCA listserve for dynamic, cross-cutting conversations with hundreds of dedicated advocates.

Fighting for Choice Together

All of our voices must be heard to protect and expand access to real choices for everyone who needs them. Especially when it comes to sexual health, which is so often stigmatized and often profoundly under threat. AVAC condemns last month’s decision by the US Supreme Court, which rolls back decades of protections for those seeking safe abortion services in the US and undermines other landmark rulings that safeguard fundamental human rights, privacy and personal liberty.

Read AVAC’s statementRead AVAC’s statement condemning the opinion and declaring our commitment to stand always for reproductive justice and to work with our partners and allies to ensure that the right to abortion is protected.

Learn More About the Impact of Media Science Cafés in Zimbabwe

For more than a decade, AVAC and partners have been leading Media Science Cafés, a program connecting journalists, researchers and advocates to help expand and deepen accurate reporting of HIV science. The program began in Uganda, when a group of journalists were looking for ways to connect with research and better understand both the science of HIV and its impact on their communities. These Cafés began with a focus on HIV with support from the Gates Foundation and the USAID-funded Coalition to Accelerate & Support Prevention Research (CASPR) and have expanded over the years to cover research on sexual and reproductive health and other health issues and, more recently with support from the Rockefeller Foundation, to COVID-19, and are now running, in partnership with health media associations, in Kenya, Uganda, Zambia, and Zimbabwe.

In a blog, Changing Minds: Journalists see a universe of genders, South African journalist, Mandi Smallhorne-Kraft tells the story of how one Café in Zimbabwe, as part of the 2019 program to connect journalists with transgender people, made a critical connection that participants called transformational. It’s a must read. Follow this link to read more.

A 15-Year Review of the PEPFAR Support to Malawi: How Has It Succeeded?

Maureen is the African Region Advocacy Advisor for AVAC. This post originally appeared in the Petrie-Flom Center at Harvard Law School’s Bill of Health.

Malawi was listed as one of the six locations that have made remarkable progress towards ending the AIDS epidemic in a recent report produced by amfAR, AVAC and Friends of the Global Fight. Being one of the poorest countries on the list, Malawi has proven that ending the epidemic is possible anywhere.

But one would want to know what has contributed to this success!

Well, there are many factors. And funding from donors is one of them. The HIV/AIDS response in Malawi is largely funded by the Global Fund and PEPFAR. But for the sake of this blog I will focus on PEPFAR, a US government program launched in 2003 by then President George W. Bush. In 15 years of support, PEPFAR has led the world in funding the global HIV response.

In Malawi, PEPFAR has invested nearly $700 million since 2003, which has brought significant improvements in the HIV/AIDS response.

But as you know, funding alone does not guarantee success. There are other factors that have played a role, such as increasing efficiency in the use of the resources, linking funding to performance and impact, having the right policies in place and widening stakeholder involvement, just to mention a few.

PEPFAR’s attention to geographical locations that carry a high burden of HIV incidence has resulted in funds going where they are needed most. PEPFAR has fought hard for the adoption of evidence-based policies, which in turn led to the implementation of the highest impact interventions.

PEPFAR’s strong recommendation to shift from paper to electronic medical records (EMR) has been another game changer for the HIV response in Malawi. Shifting to EMR improved real time access to data throughout the health care system.

Determined, Resilient, Empowered, AIDS-free, Mentored and Safe (DREAMS), a PEPFAR program meant to reduce HIV infections among adolescent girls and young women, has been another remarkable initiative rolled out to three districts in Malawi. The program has helped improved the socio-economic wellbeing of adolescent girls and young women, thereby reducing their HIV risk.

The HIV response took another important leap forward when PEPFAR opened up its doors to civil society organizations (CSOs). For me, this was proof of the principle that the best results come when funding and policy decisions are made in the presence of everyone who matters.

I remember attending the first country operational plan (COP) meeting where CSOs were invited. It was a revolutionary moment. Having CSOs in the room changed the course of the discussion. For the first time, we had everyone who mattered in the room. The following year we did it again and we are still doing it now.

But there have been challenges too! The first two years following PEPFAR’s inclusion of CSOs, civil society received limited access to PEPFAR data — it was shared late or not at all. This made it difficult for CSOs to effectively engage in the process. CSOs advocated for a change, and PEPFAR leadership has responded by making the data available, though not always timely. But we are getting there.

The other challenge has been getting policies fully implemented. A policy on paper alone is as good as no policy at all. This has been a big challenge for Malawi largely due to limited funding. Malawians can point to a full range of policies now in place, but yet some of them are live only on the books such as the Pre-Exposure Prophylaxis (PrEP) and the T=T/U=U campaigns, both of which have proven to be highest impact interventions elsewhere!

Moving forward a few things need more attention.

We all love the DREAMS program, but only focusing on three districts is not enough. It is time to scale it up!

As we get closer to epidemic control it’s important that we start thinking about how are we going to sustain the gains made so far. PEPFAR has committed to direct 70 percent of the funding to host country governments or organizations by the end of 2020 — this is highly commendable. However, this should not only be on paper, it has to be fully implemented. Lack of capacity should not be an excuse. Deliberate effort must be made to fill any gaps in capacity.

We need to embrace the model of differentiated service delivery to meet the diverse needs of the community members! To date we still have community members who travel a distance of more than 20 kilometers on foot just to get their ART refill! This is not acceptable! We need to get the services closer to them!

And, above all, policies must be fully implemented.

US National HIV/AIDS Strategy Gets A Reboot

Kevin Fisher is an AVAC staff member.

When the Obama administration released first US National HIV/AIDS Strategy (NHAS) in 2010 it was an overdue step forward and the product of years of advocacy. How could the US—with the eighth highest number of people living with HIV (PLWA)—have no strategy for getting more PLWA into care and reducing infections and health disparities?

Now on the fifth anniversary of the first NHAS, under the leadership of the Office of National AIDS Policy (ONAP), the NHAS is getting a reboot. The updated NHAS has renewed the focus on those most affected by HIV: gay and bisexual men of all races, but especially black men, heterosexual black women and men, young people, people who inject drugs and transgender women. There will be prioritization on places, like the southern US—where nationally 50 percent of new infections now occur—and key metropolitan areas. It takes responsibility for improving viral suppression and access to care in the US treatment cascade, which now lags behind many European, and some African countries. While not explicitly linked to the UNAIDS 90-90-90 goal, this new US strategy does align with the global focus on improving diagnosis, linkage to care and viral suppression. And, happily, this strategy puts the treatment cascade into the more comprehensive needs of primary prevention and addressing stigma and discrimination.

Even if the overall goals of the original NHAS—reducing infections, improving outcomes, eliminating disparities and a coordinated response—remain the same in the revised version, much has changed since 2010. In 2010 the iPrEx trial results first showed that pre-exposure prophylaxis (PrEP) is an effective HIV prevention option. In 2011 the HPTN 052 trial showed treatment and viral suppression can reduce risk of transmitting the virus and just recently, in 2015, data from both 052 and START showed that early treatment improves health outcomes for people living with HIV. The revised NHAS embraces these scientific advances adding new goals to improve the US treatment cascade, and making full access to PrEP services a cornerstone of the strategy. The full-throated endorsement of PrEP is welcome, needed, and will hopefully have impact.

The NHAS also importantly acknowledges the essential role of research in providing new tools and methods of achieving the goals of the strategy. The NHAS is unabashedly positive about research, with particular emphasis on research priorities for PrEP and innovative approaches to preventing new infections, importantly strengthening the case that now is not the time to scale back.

The updated strategy does make an important change from its predecessor, which raises some concern. The revised NHAS abandons incidence in favor of HIV diagnosis as a measure of the impact of prevention. ONAP believes it does not have the data to measure incidence, particularly in the context of increased testing. Do the data reflect higher rates of infection, or are more people being tested? This makes methodological sense but raises the question of how the impact of specific prevention interventions, or combination prevention, can be measured and assessed. The HIV field needs a tool to measure incidence to judge impact.

There will be more detail of the revised NHAS to come. A federal action plan for the revised NHAS is expected on Dec 1, 2015 and will operationalize the strategy. Now is the time for advocates and civil society to weigh in with ONAP on how these goals might be achieved in communities across the US.

Have a question about NHAS? Join the conversation on social media via #HIV2020 or Tweet your questions to @AIDSgov.

Visit aids.gov for more and download one-page infographics on “what you need to know” regarding the updated NHAS and one that outlines the five major changes since 2010.

AVAC’s HIV Testing Blog Series #1: Can HIV Self-Testing Help Slow the Epidemic?

On July 17th, the World Health Organization Released new consolidated guidelines on HIV testing services that bring together new and existing recommendations on the intervention that WHO calls “the gateway to prevention services and life-saving treatment and care.” HIV testing is also the first “90” in the UNAIDS Fast Track targets that seek to have 90 percent of people living with HIV tested, 90 percent of those individuals tested on ART, and 90 percent of those on ART virologically suppressed by 2020. Given that WHO estimates just 51 percent of people living with HIV know their status, there’s much work to be done on the testing front. The new consolidated guidance provides recommendations for lay provider testing (e.g., not by a medical professional) and advises countries on how best to target.

AVAC will be delving into various aspects of the advocacy, policy and implementation landscape around testing in P-Values posts in the coming months. In this blog, by veteran HIV journalist Mark Mascolini, we take a look at self-testing—an intervention that doesn’t yet have full WHO guidance, but is on the horizon.

How would you rate a personal diagnostic system that’s accurate, easy-to-use, private, and completely confidential? Five stars, perhaps, until you learn that it costs more than many who need it most say they can pay, misses all diagnoses in a key disease period, and may inspire false—and risky—confidence. That quick take on the pros and cons of HIV self-testing distills a slowly swelling data cache, a World Health Organization (WHO) Technical Update, and two well-reasoned analyses of new technologies that could change the way many high-risk people learn they carry HIV and may even limit HIV transmissions. But research has yet to nail down whether the clear benefits of self-testing outweigh potential drawbacks. In its new guidelines on HIV testing services WHO says that there “promising evidence” for the acceptability of self-testing and recommends implementation through country demonstration projects and pilot programmes, but stops short of a general recommendation. For this, WHO says it will wait for data from several trials whose results are expected in 2015/2016.

In the meantime, though, there’s a wealth of information for advocates and activists to consider.

Possible pluses and minuses of HIV self-testing

Pluses

Minuses

Privacy

Cannot detect early infection

Anonymity

Requires self-motivation for follow-up

Ease of use

Misunderstanding of procedure, interpretation

Accuracy

Mental distress over positive result

Testing option for high-risk people

Cost impact on access

Mutual testing of sex partners

Partner coercion

Easier repeat testing, for example, for PrEP

Condom-free sex after negative result

Wider HIV testing lowers late-diagnosis rate

Missed opportunity for STI screening

Where does testing fit in to “ending AIDS??

Testing is the cornerstone of the UNAIDS launched the 90-90-90 initiative, which aims to ensure that 90 percent of everyone living with HIV know their HIV status by 2020, and that 90 percent of those individuals are on ART and 90 percent of individuals on ART are virologically suppressed.

Just achieving the first 90—the testing goal—is a major undertaking. UNAIDS estimates that that 54 percent of people living with HIV across the globe don’t know they’re infected, To reach that goal, many countries are launching plans to massively expand HIV testing—and the draft versions of PEPFAR country operation plans that circulated earlier in 2015 bore this out with funding and detailed national planning. Much of this expansion is focused on linking people who test positive to ART; there is far less discussion of how testing could be used as an entry point for additional prevention services, including PrEP, for people who are HIV negative. But for PrEP-watchers, this is a key concern. Leveraging testing expansion as an entry point for effective prevention could revolutionize HIV prevention; in addition,  safe and effective PrEP use requires HIV testing on a regular basis to ensure that the mono- or dual-therapy is not being used by someone who has acquired HIV.

Is self-testing a partial solution?
With all of this context, the question remains: How can public health authorities expand HIV testing when many high-risk people avoid it because they fear stigma and discrimination—especially if they test positive? HIV self-testing—usually done at home—could be a big part of the answer because it’s completely private. All HIV self-tests are easy to use, though users must be able to read and understand instructions. Studies of the oral HIV self-test found that more than 80 percent of users understood how to use the kit and interpret the results. Research involving untrained self-testers found low operator error rates ranging from 0.37 to 5.4 percent.

No one doubts the demand for confidential self-testing systems. Two recent systematic reviews of self-test studies in the US, Europe, Asia, and Africa figured that 70 percent of potential users in one analysis and up to 84 percent in another found current HIV self-test kits acceptable, and high proportions thought them easy to use. And it seems clear that home-use kits can reach high-risk people. An FDA modeling study of an oral fluid diagnostic test predicted that 2.8 million people would use the test in 1 year and that it would prevent 4,000 new HIV transmissions. Half of the participants in another analysis said the self-test was their first HIV test. In countries that license HIV self-tests, kits can be bought off the shelves of many pharmacies or purchased online. Vending machines may one day dispense HIV self-tests.

Ready access to these tests, and their confidentiality, could encourage repeat use by high-risk people and facilitate the regular HIV testing necessary for effective PrEP. (UNITAID issued a call for proposals on PrEP that could include an HIV self-test.) A trusted self-test could promote mutual testing by sex partners. One systematic review determined that 80 to 97 percent of test users reported partner testing. Some research suggests rapid self-test kits will enable joint testing by new partners and could alter subsequent sexual behavior. Research confirms the intuitive assumption that wider HIV testing cuts the late-diagnosis rate and thus improves individual HIV care.

Current self-test devices use either a spot of blood from a finger pin-prick or oral fluid swabbed from the mouth. A systematic review found that potential users consistently preferred the oral test over the finger-prick. The oral test may yield an incorrect result a bit more often than the blood tests (see table below), but all tests licensed by regulatory agencies are highly reliable. WHO cautions though, that user errors and local HIV prevalence can affect self-test accuracy. People who want to buy an HIV test online should make sure regulators have licensed the test they seek because unlicensed tests may be less accurate.

Cost and inability to detect HIV in the early months of infection are two prime drawbacks of current HIV self-tests. For example, two licensed tests in the United States cost about US$40 per kit, while a test licensed in the United Kingdom in 2015 costs £30 (USD$46) Most survey respondents in self-test studies said they would not pay more than US$20 for such a test. In many regions, the poorest people are those with the highest HIV burden, so high cost could undercut the HIV-preventing potential of self-testing.

All current self-tests detect HIV antibodies, which take time to develop in a newly infected person. Almost everyone will have detectable antibodies within three months of infection, but before that someone can be HIV-positive and still test negative on an HIV self-test kit or other HIV antibody tests. Health experts fear that a negative self-test in the first weeks of HIV infection—when viral load and the potential for HIV transmission are highest—could lead some people to feel safe having sex without a condom. Because self-tests detect antibodies, they cannot be used in infants, who carry maternal HIV antibodies even if they are HIV-negative themselves.

The newest HIV self-tests give results in 15 to 20 minutes at home. Some health authorities fear that people who test positive at home may be less likely to seek counseling (which self-test makers facilitate) and less likely to enter care than people who test positive in a center where health workers read rapid-test results and counsel people immediately. If people self-test because they fear stigma, the same fear may keep them from seeking counseling or care. People with limited phone or internet access, some worry, would have a harder time seeking counseling and starting care. And if sexually active people can test themselves for HIV at home, they may be less likely to get tested regularly for other sexually transmitted diseases.

Another conceivable drawback of self-testing is that partners will coerce their mates into testing themselves and even abuse them if they don’t or if they test positive. Data supporting or disproving these hypotheses remain limited, and WHO reports no accounts of human rights violations or violence associated with self-testing.

Comparing three representative HIV self-tests

 

Home Access HIV-1 Test System

OraQuick In-Home HIV Test

BioSure HIV Self Test

Licensed

1996 in USA

2012 in USA

2015 in UK

Where can I get it?

Online or by phone

Drug stores

Online

How it works

Blood sample from finger-prick sent to lab.

Oral fluid from mouth swab put in testing device.

Blood sample from finger-prick put in testing device.

How long does it take to get results?

Three to seven business days after you mail test sample.*

20 to 40 minutes

15 minutes

What happens next?

If you test positive, the lab runs a second confirming test.

If you test positive, you must go to testing center or medical clinic for a confirming test.

If you test positive, you must go to testing center or medical clinic for a confirming test.

What else does the testing company provide?

If you test positive on a first test and follow-up test, company provides confidential counseling and referral to an HIV provider in your area.

If you test positive on a first test, company provides confidential counseling and referral for a confirming test.

If you test positive, company offers online assistance to find testing center for a confirming test.

How soon after HIV infection will the test show a positive result?

Test detects HIV antibodies, not HIV itself. Antibodies take 3 to 6 months to develop after infection.

Test detects HIV antibodies, not HIV itself. Antibodies take 3 to 6 months to develop after infection.

Test detects HIV antibodies, not HIV itself. Antibodies take 3 to 6 months to develop after infection.

How accurate is the test?

More than 99.9% of people who are HIV positive will get a positive result. More than 99.9% of people who are negative will get a negative result.

About 92% of people who are HIV positive will get a positive result. That means up to 1 in 12 positive people may get a negative result. Up to 99.98% of people who are negative will get a negative result. About 1 in 5000 results will be false-positive.

99.7% of people who are HIV positive will get a positive result, while 99.9% of people who are negative will get a negative result.

What HIV strains can it detect?

HIV-1

HIV-1 and HIV-2

HIV-1 and HIV-2

How much does it cost?

About $40

About $40

About £30

*Or on day sample arrives in lab with more expensive express service.

A WHO Technical Update concludes that “HIV self-testing has the potential to increase access to HIV testing including among people living with HIV without their knowledge, and those who are in need of HIV care, treatment and support.” The WHO document offers a clear summary of policy and regulatory considerations for policy makers and implementers.

AVAC Team Member Honored at the White House: A champion of refugee rights

On June 25, Micheal Ighodaro, an AVAC team member and leading activist for the rights of LGBT activists, was honored by the US government as a “Champion of Change” for the rights of refugees. In a ceremony at the White House, Micheal was recognized for his vocal advocacy for the rights and needs of men and women who are subject to persecution, discrimination and violence because of who they love—and who too often find themselves forced to leave their countries of origin, navigating new cultures, health and housing systems, as well as the process of obtaining asylum.

As policy and program assistant at AVAC, Micheal is working with allies across sub-Saharan Africa to define agendas that address health and human rights for all. A video of the panel discussion featuring Micheal and his fellow honorees can be viewed here, details of all the champions are available now; and a blog post from Micheal about his experiences as a refugee, activist and proud gay man is available on the White House website!

AVAC is proud to work with Micheal and salutes all of the champions recognized today.

Support the Global Response to HIV/AIDS, Tuberculosis, and Malaria

The United States Congress is currently considering the future budget of the President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria. Members of Congress are encouraging you to reach out to your representatives and advocate for strong funding.

Barbara Lee, a member of Congress from California, provides more information in a note below, including a call to sign on to her letter to other members of Congress.

Dear Colleague:

I urge you to sign on to the letter below requesting funding to support the President’s Emergency Plan for AIDS Relief (PEPFAR), the Global Fund to Fight AIDS, Tuberculosis, and Malaria in the FY 2016 State and Foreign Operations appropriations bill.

The U.S.’s bipartisan commitment to PEPFAR and the Global Fund not only saves lives, but also contributes directly to stability, security and economic growth worldwide. Our strong support for PEPFAR and the Global Fund, coupled with scientific advances and lessons learned from a decade of implementation, has the potential to turn the tide on HIV/AIDS and help us meet our target of achieving an AIDS-free generation.

These contributions are just a fraction of 1% of the federal budget, yet enable PEPFAR and the Global Fund to continue its critical, life-saving work and influence the organization’s ability to leverage additional resources from other donors. Strong support for both PEPFAR and the Global Fund will enhance U.S. leadership in the world and increase our ability to meet seminal global health goals that are within reach.

A copy of the letter is below. If you need further information or would like to sign on, please contact Monica Pham in Rep. Lee’s office (monica.pham@mail.house.gov).

Sincerely,
Barbara Lee
Member of Congress

Letters to Congress

A letter to members of the United States House of Representatives is below. Click here to download a letter for the United States Senate.

The Honorable Kay Granger
Chairwoman
Appropriations Subcommittee for
State and Foreign Operations
U.S. House of Representatives
Washington, DC 20515

The Honorable Nita Lowey
Ranking Member
Appropriations Subcommittee for
State and Foreign Operations
U.S. House of Representatives
Washington, DC 20515